Disease-Free Survival

• 

  Subject Areas on Research

  • "Extraoperative" MRI (eoMRI) for Brain Tumor Surgery: Initial Results at a Single Institution. 
  • "Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy. 
  • 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). 
  • 73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer. 
  • A Contemporary Analysis of Heart Transplantation and Bridge-to-Transplant Mechanical Circulatory Support Outcomes in Cardiac Sarcoidosis. 
  • A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure. 
  • A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report. 
  • A Machine-Based Approach to Preoperatively Identify Patients with the Most and Least Benefit Associated with Resection for Intrahepatic Cholangiocarcinoma: An International Multi-institutional Analysis of 1146 Patients. 
  • A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer. 
  • A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): A report from the Children's Oncology Group. 
  • A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. 
  • A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases. 
  • A comparison of laparoscopically assisted and open colectomy for colon cancer. 
  • A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group. 
  • A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma. 
  • A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer. 
  • A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancer. 
  • A functional variant at miRNA-122 binding site in IL-1a 3' UTR predicts risk of recurrence in patients with oropharyngeal cancer. 
  • A general formulation for a one-sided group sequential design. 
  • A genomic-augmented multivariate prognostic model for the survival of natural-killer/T-cell lymphoma patients from an international cohort. 
  • A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma. 
  • A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. 
  • A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma. 
  • A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer. 
  • A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma. 
  • A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors. 
  • A parametric model for long-term follow-up data from phase III breast cancer clinical trials. 
  • A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. 
  • A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. 
  • A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. 
  • A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. 
  • A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. 
  • A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). 
  • A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. 
  • A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. 
  • A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma. 
  • A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. 
  • A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. 
  • A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. 
  • A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors. 
  • A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study. 
  • A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. 
  • A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). 
  • A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. 
  • A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. 
  • A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. 
  • A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. 
  • A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). 
  • A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. 
  • A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. 
  • A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. 
  • A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study. 
  • A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. 
  • A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. 
  • A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. 
  • A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. 
  • A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. 
  • A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. 
  • A pretreatment nomogram for prediction of biochemical failure after primary cryoablation of the prostate. 
  • A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. 
  • A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy. 
  • A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. 
  • A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer. 
  • A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. 
  • A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. 
  • A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer. 
  • A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. 
  • A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. 
  • A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. 
  • A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. 
  • A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. 
  • A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258). 
  • A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. 
  • A reduced-toxicity regimen is associated with durable engraftment and clinical cure of nonmalignant genetic diseases among children undergoing blood and marrow transplantation with an HLA-matched related donor. 
  • A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. 
  • A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery. 
  • A statistic for comparing two correlated markers which are prognostic for time to an event. 
  • A structured literature review to determine the use of the American Society for Therapeutic Radiology and Oncology consensus definition of biochemical failure. 
  • A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. 
  • A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. 
  • A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US. 
  • ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. 
  • ABO blood group influences transfusion and survival after cardiac surgery. 
  • ACR Appropriateness Criteria(®) Locoregional therapy for resectable oropharyngeal squamous cell carcinomas. 
  • ACR Appropriateness criteria® for nasopharyngeal carcinoma. 
  • ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI. 
  • AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. 
  • ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer. 
  • ASO Visual Abstract: Survival Benefit of Chemotherapy According to 21-Gene Recurrence Score in Young Women with Breast Cancer. 
  • Abciximab readministration: results of the ReoPro Readministration Registry. 
  • Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. 
  • Ability of heart rate variability to predict prognosis in patients with advanced congestive heart failure. 
  • Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. 
  • Abiraterone in metastatic prostate cancer without previous chemotherapy. 
  • Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. 
  • Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. 
  • Accuracy of intraoperative gross examination of surgical margin status in women undergoing partial mastectomy for breast malignancy. 
  • Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment. 
  • Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors. 
  • Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure? 
  • Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. 
  • Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. 
  • Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial. 
  • Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. 
  • Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. 
  • Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. 
  • Adenocarcinoma Ex-Goblet Cell: a Retrospective Experience. 
  • Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined-modality therapy. 
  • Adherence to quality indicators and survival in patients with breast cancer. 
  • Adjuvant Chemotherapy After Preoperative Chemoradiation Improves Survival in Patients With Locally Advanced Rectal Cancer. 
  • Adjuvant Hepatic Artery Infusion Chemotherapy is Associated With Improved Survival Regardless of KRAS Mutation Status in Patients With Resected Colorectal Liver Metastases: A Retrospective Analysis of 674 Patients. 
  • Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. 
  • Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. 
  • Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. 
  • Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. 
  • Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. 
  • Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases. 
  • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. 
  • Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. 
  • Adjuvant radiation therapy increases disease-free survival in stage IB Merkel cell carcinoma. 
  • Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. 
  • Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update. 
  • Adjuvant sequential chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil (ACMF) with concurrent radiotherapy in resectable advanced breast cancer. 
  • Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy? 
  • Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. 
  • Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning. 
  • Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens. 
  • African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. 
  • Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. 
  • Aggressive (epithelioid) osteoblastoma arising in soft tissue. 
  • Aggressive multimodality treatment of invasive thymic carcinoma. 
  • Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. 
  • Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. 
  • Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs. 
  • Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. 
  • Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. 
  • Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival. 
  • American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. 
  • American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. 
  • Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. 
  • An Australian experience with temozolomide for the treatment of recurrent high grade gliomas. 
  • An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204). 
  • An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. 
  • An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. 
  • An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). 
  • Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. 
  • Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. 
  • Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. 
  • Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization. 
  • Anatomic tumor location influences the success of contemporary limb-sparing surgery and radiation among adults with soft tissue sarcomas of the extremities. 
  • Anger proneness predicts coronary heart disease risk: prospective analysis from the atherosclerosis risk in communities (ARIC) study. 
  • Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma. 
  • Angiosarcoma after breast-conserving therapy: long-term outcomes with hyperfractionated radiotherapy. 
  • Ankle-brachial index as a predictor of coronary disease events in elderly patients submitted to coronary angiography. 
  • Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). 
  • Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). 
  • Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. 
  • Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. 
  • Aortic arch atheroma progression and recurrent vascular events in patients with stroke or transient ischemic attack. 
  • Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. 
  • Appendiceal carcinoma: patterns of failure following surgery and implications for adjuvant therapy. 
  • Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804. 
  • Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. 
  • Assessing surrogacy using restricted mean survival time ratio for overall survival in non-small cell lung cancer immunotherapy studies. 
  • Assessing the Utility of Post-Mastectomy Imaging after Breast Reconstruction. 
  • Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). 
  • Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). 
  • Associating liver partition and portal vein ligation for staged hepatectomy in patients with primary liver malignancies: A systematic review of the literature. 
  • Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). 
  • Association between miRNA-binding site polymorphisms in double-strand break repair genes and risk of recurrence in patients with squamous cell carcinomas of the non-oropharynx. 
  • Association between neoadjuvant chemoradiation and survival for patients with locally advanced rectal cancer. 
  • Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer. 
  • Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study. 
  • Association between the V109G polymorphism of the p27 gene and the risk and progression of oral squamous cell carcinoma. 
  • Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. 
  • Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer. 
  • Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. 
  • Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial. 
  • Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. 
  • Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. 
  • Association of distant recurrence-free survival with algorithmically extracted MRI characteristics in breast cancer. 
  • Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. 
  • Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell System. 
  • Auto-SCT for AML in second remission: CALGB study 9620. 
  • Autologous stem cell transplantation for autoimmune diseases: issues in protocol development. 
  • Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. 
  • Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer. 
  • B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality. 
  • B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. 
  • Barriers to follow-up care of survivors in the United States and the United Kingdom. 
  • Baseline Hemodynamics and Response to Contrast Media During Diagnostic Cardiac Catheterization Predict Adverse Events in Heart Failure Patients. 
  • Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. 
  • Bevacizumab for the treatment of high-grade glioma. 
  • Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. 
  • Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. 
  • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. 
  • Beyond mere obesity: effect of increasing obesity classifications on hysterectomy outcomes for uterine cancer/hyperplasia. 
  • Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer. 
  • Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. 
  • Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. 
  • Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. 
  • Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. 
  • Breast cancer in patients treated for Hodgkin's disease: clinical and pathological analysis of 76 cases in 63 patients. 
  • Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. 
  • Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience. 
  • CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. 
  • CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. 
  • CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. 
  • CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. 
  • CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. 
  • CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases. 
  • CD8, FoxP3, and CD45RO+ Lymphocytic Infiltrates in Type I and Type II Endometrial Cancers in African American and European American Females. 
  • CXCR4 expression predicts patient outcome and recurrence patterns after hepatic resection for colorectal liver metastases. 
  • Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. 
  • Cancer control after low-dose-rate prostate brachytherapy performed by a multidisciplinary team with no previous prostate brachytherapy experience. 
  • Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). 
  • Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX. 
  • Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. 
  • Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy. 
  • Cardiac-resynchronization therapy for the prevention of heart-failure events. 
  • Cardiovascular risk factors predictive for survival and morbidity-free survival in the oldest-old Framingham Heart Study participants. 
  • Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. 
  • Changes on Midchemoradiation Therapy Fluorodeoxyglucose Positron Emission Tomography for Cervical Cancer Are Associated with Prognosis. 
  • Chemoradiation for patients with advanced oral cavity cancer. 
  • Chemoradiation for patients with large-volume laryngeal cancers. 
  • Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue. 
  • Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance). 
  • Chemotherapy in the elderly. 
  • Chemotherapy or Combined Modality Therapy for Early-stage Hodgkin Lymphoma. 
  • Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. 
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. 
  • Cigarette Smoking and Incident Stroke in Blacks of the Jackson Heart Study. 
  • Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. 
  • Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. 
  • Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. 
  • Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. 
  • Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. 
  • Clinical and in vitro studies of imatinib in advanced carcinoid tumors. 
  • Clinical and pathologic correlates in surgical stage II endometrial carcinoma. 
  • Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. 
  • Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial. 
  • Clinical outcome after neoadjuvant thermoradiotherapy in high grade soft tissue sarcomas. 
  • Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. 
  • Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. 
  • Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer. 
  • Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the Surveillance, Epidemiology, and End Results registry. 
  • Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. 
  • Clinical pathway to screen for cardiac amyloidosis in heart failure with preserved ejection fraction. 
  • Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. 
  • Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. 
  • Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. 
  • Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation. 
  • Clinicopathological Features and Prognosis of Mixed-Type T1a Gastric Cancer Based on Lauren's Classification. 
  • Clinicopathological characteristics and outcomes of surgically excised renal masses in African Americans. 
  • Clinicopathological data and treatment modalities for pancreatic vipomas: a systematic review. 
  • Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. 
  • Collagenase specificity in chondrosarcoma metastasis. 
  • Colorectal cancer: adjuvant chemotherapy for rectal cancer-an unresolved issue. 
  • Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. 
  • Combined external beam irradiation and external regional hyperthermia for locally advanced adenocarcinoma of the prostate. 
  • Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications. 
  • Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance). 
  • Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. 
  • Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States. 
  • Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review. 
  • Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study. 
  • Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. 
  • Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. 
  • Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. 
  • Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank). 
  • Comparison of diagnostic markers with repeated measurements: a non-parametric ROC curve approach. 
  • Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). 
  • Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. 
  • Comparison of non-myeloablative conditioning regimens for lymphoproliferative disorders. 
  • Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. 
  • Comparison of results of percutaneous balloon mitral commissurotomy in patients aged > or = 65 years with those in patients aged < 65 years. 
  • Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02). 
  • Complementary roles of open and hybrid approaches to thoracoabdominal aortic aneurysm repair. 
  • Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. 
  • Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients. 
  • Complete remission seven years after treatment for metastatic malignant melanoma. 
  • Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. 
  • Comprehensive analysis of chromosome 1p deletions in neuroblastoma. 
  • Computed Tomography Image Texture: A Noninvasive Prognostic Marker of Hepatic Recurrence After Hepatectomy for Metastatic Colorectal Cancer. 
  • Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment. 
  • Concomitant chemotherapy and radiotherapy for locally advanced nasopharyngeal carcinoma. 
  • Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. 
  • Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. 
  • Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. 
  • Conditional disease-free survival after surgical resection of gastrointestinal stromal tumors: a multi-institutional analysis of 502 patients. 
  • Confirmatory Magnetic Resonance Imaging with or without Biopsy Impacts Decision Making in Newly Diagnosed Favorable Risk Prostate Cancer. 
  • Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. 
  • Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. 
  • Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. 
  • Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. 
  • Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. 
  • Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. 
  • Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. 
  • Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria - analysis from the @-Registry. 
  • Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada. 
  • Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer. 
  • CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. 
  • Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials. 
  • Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. 
  • Cryosurgery after chemoembolization for hepatocellular carcinoma in patients with cirrhosis. 
  • Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review. 
  • Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. 
  • Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. 
  • Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival. 
  • Cytokine use and survival in the first-line treatment of ovarian cancer: a Gynecologic Oncology Group Study. 
  • DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML). 
  • Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion. 
  • Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. 
  • Decreased cancer-independent life expectancy in the head and neck cancer population. 
  • Defining best supportive care. 
  • Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guidelines: A multi-institutional analysis of 1,010 patients. 
  • Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. 
  • Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. 
  • Descriptive characteristics of prostate cancer in patients with a history of primary male breast cancer - a SEER analysis. 
  • Designing a Rational Follow-Up Schedule for Patients with Extremity Soft Tissue Sarcoma. 
  • Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. 
  • Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer. 
  • Detection of silent ischemia adds to the prognostic value of coronary anatomy and left ventricular function in predicting outcome in unstable angina patients. 
  • Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? 
  • Development of a protocol for allogeneic marrow transplantation for severe systemic sclerosis: paradigm for autoimmune disease. 
  • Development, validation, and application of a microsimulation model to predict stroke and mortality in medically managed asymptomatic patients with significant carotid artery stenosis. 
  • Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. 
  • Different cellular p16(INK4a) localisation may signal different survival outcomes in head and neck cancer. 
  • Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors. 
  • Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing. 
  • Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. 
  • Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials. 
  • Disorders of glucose homeostasis in young adults treated with total body irradiation during childhood: a pilot study. 
  • Do Largest Basal Tumor Diameter and the American Joint Committee on Cancer's Cancer Staging Influence Prognostication by Gene Expression Profiling in Choroidal Melanoma. 
  • Do cardiac troponins provide prognostic insight in hemodialysis patients? 
  • Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. 
  • Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer? 
  • Does prior benign prostate biopsy predict outcome for patients treated with radical perineal prostatectomy? 
  • Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission? 
  • Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer? 
  • Does the number of lymph nodes examined in patients with lymph node-negative breast carcinoma have prognostic significance? 
  • Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. 
  • Does vocal cord fixation preclude nonsurgical management of laryngeal cancer? 
  • Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. 
  • Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. 
  • Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854. 
  • Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. 
  • Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. 
  • Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study. 
  • Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. 
  • Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. 
  • Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. 
  • Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies. 
  • Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy. 
  • Durable Chimerism and Long-Term Survival after Unrelated Umbilical Cord Blood Transplantation for Pediatric Hemophagocytic Lymphohistiocytosis: A Single-Center Experience. 
  • Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. 
  • E-cadherin in gastric carcinomas: Relations with histological parameters and its prognostic value. 
  • E2F transcription factor 2 variants as predictive biomarkers for recurrence risk in patients with squamous cell carcinoma of the oropharynx. 
  • EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. 
  • ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. 
  • ERCC1 protein expression is associated with differential survival in oropharyngeal head and neck squamous cell carcinoma. 
  • Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG. 
  • Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. 
  • Educational attainment has a limited impact on disease management outcomes in heart failure. 
  • Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. 
  • Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. 
  • Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. 
  • Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. 
  • Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy. 
  • Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research. 
  • Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data. 
  • Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. 
  • Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. 
  • Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. 
  • Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. 
  • Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients. 
  • Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research. 
  • Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. 
  • Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. 
  • Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: a Pediatric Oncology Group report. 
  • Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. 
  • Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. 
  • Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. 
  • Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. 
  • Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. 
  • Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study. 
  • Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. 
  • Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. 
  • Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer. 
  • Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. 
  • Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. 
  • Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials. 
  • Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. 
  • Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma. 
  • Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial. 
  • Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy. 
  • Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. 
  • Elevated body mass index and intermediate-term clinical outcomes after acute coronary syndromes. 
  • Elevated cerebrospinal fluid cytokine levels in tuberculous meningitis predict survival in response to dexamethasone. 
  • Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). 
  • Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. 
  • Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. 
  • Epirubicin and ifosfamide in metastatic breast cancer. 
  • Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. 
  • Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. 
  • Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System. 
  • Ethnic differences in the prognostic value of stress technetium-99m tetrofosmin gated single-photon emission computed tomography myocardial perfusion imaging. 
  • Evaluating changes in radiation treatment volumes from post-operative to same-day planning MRI in High-grade gliomas. 
  • Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. 
  • Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. 
  • Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. 
  • Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. 
  • Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer. 
  • Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint. 
  • Evaluation of hypertension as a marker of bevacizumab efficacy. 
  • Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis. 
  • Evaluation of primary pulmonary carcinoid tumors using FDG PET. 
  • Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. 
  • Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group. 
  • Everolimus in colorectal cancer. 
  • Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. 
  • Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). 
  • Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer. 
  • Evolving practice pattern changes and outcomes in the era of hybrid aortic arch repair. 
  • Ewing's sarcoma of the hand. 
  • Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: impact on future clinical trials. 
  • Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis. 
  • Exercise has a disproportionate role in the pathogenesis of arrhythmogenic right ventricular dysplasia/cardiomyopathy in patients without desmosomal mutations. 
  • Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting. 
  • Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. 
  • Exploring the Relationship Between Patient Age and Cancer-Specific Survival in Papillary Thyroid Cancer: Rethinking Current Staging Systems. 
  • Expression and prognostic impact of lncRNAs in acute myeloid leukemia. 
  • Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. 
  • Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome. 
  • Extent of neck dissection required after concurrent chemoradiation for stage IV head and neck squamous cell carcinoma. 
  • Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. 
  • Extent of tumor fibrosis/hyalinization and infarction following neoadjuvant radiation therapy is associated with improved survival in patients with soft-tissue sarcoma. 
  • External beam radiation therapy after radical prostatectomy: efficacy and impact on urinary continence. 
  • FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. 
  • Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission. 
  • Factors Associated with Recurrence Rates and Long-Term Survival in Women Diagnosed with Breast Cancer Ages 40 and Younger. 
  • Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer. 
  • Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression. 
  • Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. 
  • Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells. 
  • Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models. 
  • Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. 
  • Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. 
  • Fine needle aspiration of osteogenic sarcoma metastatic to the lung. A report of four cases. 
  • First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. 
  • Five-Year Biochemical Progression-Free Survival Following Salvage Whole-Gland Prostate Cryoablation: Defining Success with Nadir Prostate-Specific Antigen. 
  • Five-Year Outcomes after On-Pump and Off-Pump Coronary-Artery Bypass. 
  • Five-year follow-up of the Sirolimus-Eluting Stents vs Vascular Brachytherapy for Bare Metal In-Stent Restenosis (SISR) trial. 
  • Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. 
  • Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients. 
  • Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study. 
  • Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. 
  • Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. 
  • Frailty models with missing covariates. 
  • Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. 
  • Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer. 
  • Functional status in left ventricular assist device-supported patients: a literature review. 
  • Gastric cancer pharmacogenetics: progress or old tripe? 
  • Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. 
  • Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). 
  • Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. 
  • Gene expression profile assays as predictors of distant recurrence-free survival in early-stage breast cancer. 
  • Gene expression profile assays as predictors of recurrence-free survival in early-stage breast cancer: a metaanalysis. 
  • Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. 
  • Gene expression profiling and outcome prediction in non-Hodgkin lymphoma. 
  • Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. 
  • Genetic variants in TNF-α promoter are predictors of recurrence in patients with squamous cell carcinoma of oropharynx after definitive radiotherapy. 
  • Genetic variants in glutamine metabolic pathway genes predict cutaneous melanoma-specific survival. 
  • Genetic variants in microRNA-binding sites of DNA repair genes as predictors of recurrence in patients with squamous cell carcinoma of the oropharynx. 
  • Genetic variants in the vitamin D pathway genes VDBP and RXRA modulate cutaneous melanoma disease-specific survival. 
  • Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy. 
  • Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma. 
  • Geographic Variations in Lung Cancer Lobectomy Outcomes: The General Thoracic Surgery Database. 
  • Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy. 
  • HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. 
  • Haptoglobin Genotype as a Prognostic Factor for Adverse Events in Coronary Artery Bypass Surgery in Diabetic Patients. 
  • Has there been progress in the treatment of older patients with acute myeloid leukemia? 
  • Head and neck squamous cell cancer (stages III and IV) induction chemotherapy assessment: value of FDG volumetric imaging parameters. 
  • Health status and quality of life among non-Hodgkin lymphoma survivors. 
  • Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. 
  • Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. 
  • Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial. 
  • Hematopoietic Stem Cell Transplantation for CD40 Ligand Deficiency: Single Institution Experience. 
  • Hematopoietic cell transplantation for Chediak-Higashi syndrome. 
  • Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. 
  • Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure. 
  • Hepatic arterial nodal metastases in pancreatic cancer: is this the node of importance? 
  • Hepatic pedicle clamping during hepatic resection for colorectal liver metastases: no impact on survival or hepatic recurrence. 
  • Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin. 
  • Hepatocellular Carcinoma: It Is Time to Focus on Prognosis. 
  • Hepatocellular carcinoma tumour burden score to stratify prognosis after resection. 
  • High hemoglobin A1c associated with increased adverse limb events in peripheral arterial disease patients undergoing revascularization. 
  • High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. 
  • High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. 
  • High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. 
  • High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. 
  • High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). 
  • Higher Use of Surgery Confers Superior Survival in Stage I Non-Small Cell Lung Cancer. 
  • Histologic pattern of invasion and epithelial-mesenchymal phenotype predict prognosis in squamous carcinoma of the head and neck. 
  • Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. 
  • History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. 
  • History of depression and survival after acute myocardial infarction. 
  • History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. 
  • Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. 
  • Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer. 
  • How I do it: Apalutamide use in non-metastatic castrate resistant prostate cancer. 
  • Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. 
  • ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. 
  • Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status. 
  • Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study. 
  • Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. 
  • Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. 
  • Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. 
  • Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma. 
  • Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). 
  • Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma. 
  • Impact of Peritoneal Metastasis on Survival of Patients With Small Intestinal Neuroendocrine Tumor. 
  • Impact of Positive Margins on Survival in Patients Undergoing Esophagogastrectomy for Esophageal Cancer. 
  • Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM. 
  • Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. 
  • Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. 
  • Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. 
  • Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging. 
  • Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. 
  • Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study. 
  • Impact of increases in high-density lipoprotein cholesterol on cardiovascular outcomes during the armed forces regression study. 
  • Impact of internal mammary artery conduit on long-term outcomes after percutaneous intervention of saphenous vein graft. 
  • Impact of number of nodes retrieved on outcome in patients with rectal cancer. 
  • Impact of obesity and body fat distribution on survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. 
  • Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. 
  • Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. 
  • Impact of postoperative nausea and vomiting prophylaxis with dexamethasone on the risk of recurrence of endometrial cancer. 
  • Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803. 
  • Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system. 
  • Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. 
  • Impact of time duration after neoadjuvant therapy to surgery on response and outcome in rectal cancer patients. 
  • Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. 
  • Importance of sentinel lymph node biopsy in patients with thin melanoma. 
  • Important impact of gingival and periodontal conditions on outcomes in SCT recipients. 
  • Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. 
  • Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. 
  • Improved staging in node-positive breast cancer patients using lymph node ratio: results in 1,788 patients with long-term follow-up. 
  • Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. 
  • Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma. 
  • Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib. 
  • Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases. 
  • In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database. 
  • In regard to Brenner et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio) similar to late-responding normal tissue. 
  • In regard to Lee et al.: "Dosimetry and cancer control after low-dose-rate prostate brachytherapy" (Int J Radiat Oncol Biol Phys 2005;61:52-59). 
  • In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. 
  • Incidental discovery of an appendiceal carcinoid tumor and a renal cell carcinoma. 
  • Increased survival with enzalutamide in prostate cancer after chemotherapy. 
  • Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. 
  • Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. 
  • Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. 
  • Induction chemotherapy and conformal radiation therapy for very young children with nonmetastatic medulloblastoma: Children's Oncology Group study P9934. 
  • Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study. 
  • Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial. 
  • Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. 
  • Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. 
  • Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia. 
  • Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. 
  • Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence. 
  • Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. 
  • Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). 
  • Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. 
  • Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? 
  • Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). 
  • International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. 
  • Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival. 
  • Intraductal Oncocytic Papillary Neoplasms: Clinical-Pathologic Characterization of 24 Cases, With An Emphasis on Associated Invasive Carcinomas. 
  • Intraoperative pelvic brachytherapy for treatment of locally advanced or recurrent colorectal cancer. 
  • Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer. 
  • Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer. 
  • Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure. 
  • Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients With History of Stroke Plus Diabetes Mellitus. 
  • Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma. 
  • Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. 
  • Iodized Oil Transarterial Chemoembolization and Radiofrequency Ablation for Small Periportal Hepatocellular Carcinoma: Comparison with Nonperiportal Hepatocellular Carcinoma. 
  • Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. 
  • Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database. 
  • Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. 
  • Is there a role for continuation phase cognitive therapy for depressed outpatients? 
  • Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. 
  • J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. 
  • KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas. 
  • KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. 
  • KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. 
  • Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. 
  • Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study. 
  • Laparoendoscopic single-site nephrectomy compared with conventional laparoscopic nephrectomy: a 5-year, single-surgeon experience. 
  • Laparoscopic Versus Open Adrenalectomy for Localized/Locally Advanced Primary Adrenocortical Carcinoma (ENSAT I-III) in Adults: Is Margin-Free Resection the Key Surgical Factor that Dictates Outcome? A Review of the Literature. 
  • Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. 
  • Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults. 
  • Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation. 
  • Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. 
  • Lenalidomide after stem-cell transplantation for multiple myeloma. 
  • Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. 
  • Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. 
  • Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria. 
  • Liver metastases from breast cancer: long-term survival after curative resection. 
  • Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors. 
  • Liver transplantation for the treatment of hepatocellular carcinoma. 
  • Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. 
  • Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. 
  • Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. 
  • Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. 
  • Local recurrence after surgery for non-small cell lung cancer: a recursive partitioning analysis of multi-institutional data. 
  • Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. 
  • Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. 
  • Long-term Clinical Outcomes of Nonoperative Management With Chemoradiotherapy for Locally Advanced Rectal Cancer in the Veterans Health Administration. 
  • Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. 
  • Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. 
  • Long-term follow-Up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia. 
  • Long-term follow-up after uveal melanoma charged particle therapy. 
  • Long-term follow-up of Hodgkin's disease trial. 
  • Long-term follow-up of a phase II trial studying a weekly doxorubicin-based multiple drug adjuvant therapy for stage II node-positive carcinoma of the breast. 
  • Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. 
  • Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST-elevation myocardial infarction. 
  • Long-term oncologic outcomes for simultaneous resection of synchronous metastatic liver and primary colorectal cancer. 
  • Long-term outcome after biologic versus mechanical aortic valve replacement in 841 patients. 
  • Long-term outcomes after lobectomy for non-small cell lung cancer when unsuspected pN2 disease is found: A National Cancer Data Base analysis. 
  • Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb. 
  • Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL. 
  • Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. 
  • Long-term results of endovascular repair for descending thoracic aortic aneurysms. 
  • Long-term survival after spontaneous rupture of a malignant rhabdoid tumor of the liver. 
  • Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. 
  • Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. 
  • Long-term survival following total sacrectomy with reconstruction for the treatment of primary osteosarcoma of the sacrum. A case report. 
  • Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. 
  • Longterm followup and quality of life after hematopoietic stem cell transplantation. 
  • Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. 
  • Low levels of BRCA1 protein expression predict a worse prognosis in stage I-II colon cancer. 
  • Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma. 
  • Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. 
  • Low-grade glioma. 
  • Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. 
  • Lower heart rate in the early postoperative period does not correlate with long-term outcomes after repair of type A acute aortic dissection. 
  • Lower incidence of vascular events following small artery ischemic stroke. 
  • Lymphocyte telomere length predicts clinical outcomes of HPV-positive oropharyngeal cancer patients after definitive radiotherapy. 
  • Lymphovascular space invasion in uterine corpus cancer: What is its prognostic significance in the absence of lymph node metastases? 
  • MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. 
  • MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial. 
  • MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma. 
  • Magnetic resonance imaging with gadoxetic acid for local tumour progression after radiofrequency ablation in patients with hepatocellular carcinoma. 
  • Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance). 
  • Making genuine progress against metastatic breast cancer. 
  • Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. 
  • Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. 
  • Management and outcomes in patients with moderate or severe functional mitral regurgitation and severe left ventricular dysfunction. 
  • Management of Locoregional Rectal Cancer. 
  • Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. 
  • Marine ω-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). 
  • Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance). 
  • Marked response of gliomatosis cerebri to temozolomide and whole brain radiotherapy. 
  • Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. 
  • Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. 
  • Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. 
  • Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). 
  • Medullary thyroid microcarcinoma: a population-level analysis of 310 patients. 
  • Melanoma Expression Genes Identified through Genome-Wide Association Study of Breslow Tumor Thickness. 
  • Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients. 
  • Merkel cell carcinoma: identification of prognostic factors unique to tumors located in the head and neck based on analysis of SEER data. 
  • Merkel cell carcinoma: prognosis and treatment of patients from a single institution. 
  • Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis. 
  • Mesenteric Tumor Deposits in Midgut Small Intestinal Neuroendocrine Tumors Are a Stronger Indicator Than Lymph Node Metastasis for Liver Metastasis and Poor Prognosis. 
  • Mesothelin expression is associated with poor outcomes in breast cancer. 
  • Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. 
  • Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. 
  • Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. 
  • Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape. 
  • Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer. 
  • Metformin is associated with improved survival in endometrial cancer. 
  • Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. 
  • Mitochondrial Oxidative Phosphorylation Complex Regulates NLRP3 Inflammasome Activation and Predicts Patient Survival in Nasopharyngeal Carcinoma. 
  • Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients. 
  • Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. 
  • Molecular analysis of synchronous and metachronous tumors of the lung: impact on management and prognosis. 
  • Molecular markers in prostate cancer: the role in preoperative staging. 
  • More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. 
  • Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas. 
  • Mortality rate and screening. 
  • Mucosal melanoma. 
  • Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. 
  • Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study. 
  • Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials. 
  • Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer. 
  • Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival. 
  • Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. 
  • Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. 
  • Multidisciplinary Management of Breast Cancer Brain Metastases. 
  • Multiplatform computational analysis of mast cells in adrenocortical carcinoma tumor microenvironment. 
  • Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies. 
  • Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. 
  • Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases. 
  • Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. 
  • Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. 
  • Myeloablative transplantation using either cord blood or bone marrow leads to immune recovery, high long-term donor chimerism and excellent survival in chronic granulomatous disease. 
  • NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy. 
  • Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery. 
  • Natural history of patients with subcentimeter pulmonary nodules undergoing hepatic resection for metastatic colorectal cancer. 
  • Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415. 
  • Neoadjuvant Radiation Therapy and Surgery Improves Metastasis-Free Survival over Surgery Alone in a Primary Mouse Model of Soft Tissue Sarcoma. 
  • Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer. 
  • Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. 
  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. 
  • Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. 
  • Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor. 
  • Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial. 
  • Neutrophils promote tumor resistance to radiation therapy. 
  • New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma. 
  • Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. 
  • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. 
  • Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. 
  • Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. 
  • No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. 
  • No evidence of sex-related survival disparities among head and neck cancer patients receiving similar multidisciplinary care: a matched-pair analysis. 
  • Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935. 
  • Non-Hodgkin's lymphomas, version 2.2014. 
  • Normalization of quality of life three years after temporal lobectomy: a controlled study. 
  • Novel prognostic markers for patients with triple-negative breast cancer. 
  • Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. 
  • Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. 
  • Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. 
  • Older patients with myeloma derive similar benefit from autologous transplantation. 
  • Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715). 
  • One-unit versus two-unit cord-blood transplantation for hematologic cancers. 
  • Operative morbidity and survival following hepatectomy for colorectal liver metastasis in octogenarians: a contemporary case matched series. 
  • Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. 
  • Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. 
  • Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. 
  • Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. 
  • Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. 
  • Outcomes among 562 recipients of placental-blood transplants from unrelated donors. 
  • Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. 
  • Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. 
  • Outcomes in surgical stage I uterine papillary serous carcinoma. 
  • Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. 
  • Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma. 
  • Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. 
  • Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case Series. 
  • Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia. 
  • Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. 
  • Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. 
  • Overcoming a travel burden to high-volume centers for treatment of retroperitoneal sarcomas is associated with improved survival. 
  • Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy. 
  • Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas. 
  • Oxidative changes in cerebral spinal fluid phosphatidylcholine during treatment for acute lymphoblastic leukemia. 
  • Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. 
  • PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. 
  • POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group. 
  • Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer. 
  • Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. 
  • Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. 
  • Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. 
  • Pancreas-preserving duodenectomy in the management of duodenal familial adenomatous polyposis. 
  • Paradoxical relationship between chromosomal instability and survival outcome in cancer. 
  • Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy: The NRG/RTOG 9514 and 0630 Nonrandomized Clinical Trials. 
  • Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. 
  • Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. 
  • Pathologic grade and tumor size are associated with recurrence-free survival in patients with duodenal neuroendocrine tumors. 
  • Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma. 
  • Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. 
  • Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. 
  • Pathology-based staging for HPV-positive squamous carcinoma of the oropharynx. 
  • Patient preferences in advanced or recurrent ovarian cancer. 
  • Patient-Reported Health-Related Quality of Life Is a Predictor of Outcomes in Ambulatory Heart Failure Patients Treated With Left Ventricular Assist Device Compared With Medical Management: Results From the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management). 
  • Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. 
  • Patients' understanding of oncology clinical endpoints: A literature review. 
  • Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. 
  • Patterns of exercise across the cancer trajectory in brain tumor patients. 
  • Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. 
  • Patterns of recurrence after trimodality therapy for esophageal cancer. 
  • Patterns of use of perioperative angiotensin-converting enzyme inhibitors in coronary artery bypass graft surgery with cardiopulmonary bypass: effects on in-hospital morbidity and mortality. 
  • Pediatric nonaortic arterial aneurysms. 
  • Pediatric tethered cord syndrome: response of scoliosis to untethering procedures. Clinical article. 
  • Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. 
  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. 
  • Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial. 
  • Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer. 
  • Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. 
  • Percutaneous coronary interventions and cardiovascular outcomes for patients with chronic total occlusions. 
  • Percutaneous transluminal coronary angioplasty as a first revascularization procedure in single-, double- and triple-vessel coronary artery disease. 
  • Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. 
  • Perioperative complications influence recurrence and survival after resection of hepatic colorectal metastases. 
  • Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer. 
  • Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma. 
  • Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group. 
  • Persistent N2 disease after neoadjuvant chemotherapy for non-small-cell lung cancer. 
  • Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. 
  • Phase 1 trial of neoadjuvant radiation therapy before prostatectomy for high-risk prostate cancer. 
  • Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. 
  • Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. 
  • Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. 
  • Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. 
  • Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. 
  • Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. 
  • Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. 
  • Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. 
  • Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. 
  • Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. 
  • Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. 
  • Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. 
  • Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. 
  • Phase I study of pazopanib plus TH-302 in advanced solid tumors. 
  • Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. 
  • Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. 
  • Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. 
  • Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. 
  • Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. 
  • Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test. 
  • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. 
  • Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. 
  • Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. 
  • Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. 
  • Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. 
  • Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. 
  • Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. 
  • Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. 
  • Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206. 
  • Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. 
  • Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. 
  • Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. 
  • Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. 
  • Phase II trial of gefitinib in recurrent glioblastoma. 
  • Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004). 
  • Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. 
  • Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy. 
  • Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. 
  • Phase II trial of temozolomide in patients with progressive low-grade glioma. 
  • Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. 
  • Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. 
  • Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). 
  • Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. 
  • Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. 
  • Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. 
  • Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. 
  • Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. 
  • Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. 
  • Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. 
  • Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. 
  • Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. 
  • Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. 
  • Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. 
  • Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. 
  • Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. 
  • Pheochromocytoma complicated with cardiomyopathy after delivery--a case report and literature review. 
  • Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. 
  • Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance). 
  • Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001). 
  • Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. 
  • Planned early neck dissection before radiation for persistent neck nodes after induction chemotherapy. 
  • Plasma omega-3 polyunsaturated fatty acids and survival in patients with chronic heart failure and major depressive disorder. 
  • Platinum sensitivity in metastatic prostate cancer: does histology matter? 
  • Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. 
  • Pneumoperitoneum complicating ERCP performed immediately after EUS-guided fine needle aspiration. 
  • Polymorphisms in genes encoding drug metabolizing enzymes and their influence on the outcome of children with neuroblastoma. 
  • Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. 
  • Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE). 
  • Post-radical prostatectomy management options for positive surgical margins: argument for observation. 
  • Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. 
  • Postoperative prognosis prediction of pancreatic cancer with seven microRNAs. 
  • Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. 
  • Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. 
  • Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. 
  • Potentially functional variants in the core nucleotide excision repair genes predict survival in Japanese gastric cancer patients. 
  • Potentially functional variants of p14ARF are associated with HPV-positive oropharyngeal cancer patients and survival after definitive chemoradiotherapy. 
  • Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation. 
  • Pre-miRNA variants as predictors of clinical outcome in patients with squamous cell carcinomas of the nonoropharynx. 
  • Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance). 
  • Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH. 
  • Predicting adverse outcome with exercise SPECT technetium-99m sestamibi imaging in patients with suspected or known coronary artery disease. 
  • Predicting negative mood state and personal growth in African American and White long-term breast cancer survivors. 
  • Predicting recurrence patterns after resection of hepatocellular cancer. 
  • Prediction of Recurrence Patterns from Hepatic Parenchymal Disease After Resection of Colorectal Liver Metastases. 
  • Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance). 
  • Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. 
  • Predictive factors for applicability and success with endoscopic treatment of upper tract urothelial carcinoma. 
  • Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial. 
  • Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. 
  • Predictors of Long-Term Quality of Life for Survivors of Stage II/III Rectal Cancer in the Cancer Care Outcomes Research and Surveillance Consortium. 
  • Predictors of adverse smoking outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. 
  • Predictors of appropriate implantable defibrillator therapies in patients with arrhythmogenic right ventricular dysplasia. 
  • Predictors of competing mortality in advanced head and neck cancer. 
  • Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). 
  • Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. 
  • Preoperative chemoradiotherapy for locally advanced gastric cancer. 
  • Preoperative concurrent chemotherapy and radiotherapy in rectal cancer patients. 
  • Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. 
  • Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. 
  • Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. 
  • Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance. 
  • Preoperative predictors of pathologic stage T2a in low-risk prostate cancer: implications for focal therapy. 
  • Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. 
  • Presentation and management of gastrointestinal stromal tumors of the duodenum: a multi-institutional analysis. 
  • Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). 
  • Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. 
  • Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone. 
  • Prevalence and Prognostic Significance of Left Ventricular Noncompaction in Patients Referred for Cardiac Magnetic Resonance Imaging. 
  • Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. 
  • Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry. 
  • Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables. 
  • Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinoma. 
  • Primary tumor location as a prognostic factor in metastatic colorectal cancer. 
  • Primary tumor microRNA signature predicts recurrence and survival in patients with locally advanced esophageal adenocarcinoma. 
  • Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma. 
  • Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. 
  • Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. 
  • Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). 
  • Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. 
  • Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? 
  • Prognostic features and treatment outcome in locoregionally advanced nasopharyngeal carcinoma following concurrent chemotherapy and radiotherapy. 
  • Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. 
  • Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. 
  • Prognostic implications of exercise echocardiography in women with known or suspected coronary artery disease. 
  • Prognostic modeling for patients with colorectal liver metastases incorporating FDG PET radiomic features. 
  • Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. 
  • Prognostic significance of depth of gross or microscopic perirectal fat invasion in T3 N0 M0 rectal cancers following sharp mesorectal excision and no adjuvant therapy. 
  • Prognostic significance of early recurrence: a conditional survival analysis in patients with resected colorectal liver metastasis. 
  • Prognostic significance of elevated troponin I after percutaneous coronary intervention. 
  • Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. 
  • Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. 
  • Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. 
  • Prognostic value of CT angiography in patients with inconclusive functional stress tests. 
  • Prognostic value of FDG PET metabolic tumor volume in human papillomavirus-positive stage III and IV oropharyngeal squamous cell carcinoma. 
  • Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. 
  • Prognostic value of midtreatment FDG-PET in oropharyngeal cancer. 
  • Prognostic value of radiographically defined extranodal extension in human papillomavirus-associated locally advanced oropharyngeal carcinoma. 
  • Prognostic value of the diagnostic criteria distinguishing endometrial stromal sarcoma, low grade from undifferentiated endometrial sarcoma, 2 entities within the invasive endometrial stromal neoplasia family. 
  • Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. 
  • Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. 
  • Projecting Survival in Papillary Thyroid Cancer: A Comparison of the Seventh and Eighth Editions of the American Joint Commission on Cancer/Union for International Cancer Control Staging Systems in Two Contemporary National Patient Cohorts. 
  • Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. 
  • Propensity Score-Matched Comparison of Partial to Whole-Gland Cryotherapy for Intermediate-Risk Prostate Cancer: An Analysis of the Cryo On-Line Data Registry Data. 
  • Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. 
  • Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. 
  • Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases. 
  • Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential. 
  • Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. 
  • Prostate specific antigen density is not an independent predictor of response for prostate cancer treated by conformal radiotherapy. 
  • Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. 
  • Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B. 
  • Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. 
  • Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial. 
  • Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. 
  • RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. 
  • Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). 
  • Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients. 
  • Racial differences in outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT): a comparison of whites versus blacks. 
  • Radiation therapy for oligometastatic non-small cell lung cancer. 
  • Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer. 
  • Radiofrequency ablation of liver tumors: influence of technique and tumor size. 
  • Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. 
  • Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. 
  • Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. 
  • Radiotherapy dose-response analysis for diffuse large B-cell lymphoma with a complete response to chemotherapy. 
  • Radiotherapy following radical prostatectomy. 
  • Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. 
  • Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. 
  • Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. 
  • Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). 
  • Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. 
  • Randomized multicentric study of perioperative chemotherapy with mitoxantrone in early breast cancer. 
  • Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. 
  • Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. 
  • Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. 
  • Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. 
  • Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. 
  • Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. 
  • Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. 
  • Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. 
  • Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. 
  • Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. 
  • Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. 
  • Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. 
  • Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. 
  • Randomized, placebo-controlled clinical trial of an aerosolized β₂-agonist for treatment of acute lung injury. 
  • Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. 
  • RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer. 
  • Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: data from the GUSTO-III Trial. 
  • Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. 
  • Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. 
  • Recent advances in the treatment of prostate cancer. 
  • Recognition of early mortality in multiple myeloma by a prediction matrix. 
  • Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. 
  • Recommendations for the Use of Mechanical Circulatory Support: Ambulatory and Community Patient Care: A Scientific Statement From the American Heart Association. 
  • Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. 
  • Recurrence After Partial Hepatectomy for Metastatic Colorectal Cancer: Potentially Curative Role of Salvage Repeat Resection. 
  • Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models. 
  • Recurrence Rate and Pattern of Perihilar Cholangiocarcinoma after Curative Intent Resection. 
  • Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review Study. 
  • Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002). 
  • Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. 
  • Reflecting on survivorship outcomes to aid initial decision making in patients treated for IDH-mutated anaplastic glioma. 
  • Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. 
  • Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. 
  • Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. 
  • Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI. 
  • Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials. 
  • Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. 
  • Relationship between tamoxifen use and high risk endometrial cancer histologic types. 
  • Relationship between tumor response at therapy completion and prognosis in patients with Group III rhabdomyosarcoma: A report from the Children's Oncology Group. 
  • Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. 
  • Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes. 
  • Repeat revascularization after contemporary percutaneous coronary intervention: an evaluation of staged, target lesion, and other unplanned revascularization procedures during the first year. 
  • Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. 
  • Resected pancreatic neuroendocrine tumors: patterns of failure and disease-related outcomes with or without radiotherapy. 
  • Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate? 
  • Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis. 
  • Residual disease predicts outcomes after definitive resection for incidental gallbladder cancer. 
  • Response rate as an endpoint in clinical trials. 
  • Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR). 
  • Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. 
  • Results of a phase II study of weekly paclitaxel plus carboplatin in advanced carcinoma of unknown primary origin: a reasonable regimen for the community-based clinic? 
  • Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). 
  • Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. 
  • Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. 
  • Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. 
  • Results of the cord blood transplantation study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. 
  • Retreatment of patients surviving cancer-free 2 or more years after initial treatment of small cell lung cancer. 
  • Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer. 
  • Retrospective review of an intraoperative algorithm to predict lymph node metastasis in low-grade endometrial adenocarcinoma. 
  • Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide. 
  • Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer. 
  • Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. 
  • Right-Sided Versus Left-Sided Pneumonectomy After Induction Therapy for Non-Small Cell Lung Cancer. 
  • Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. 
  • Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme. 
  • Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. 
  • Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. 
  • Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. 
  • Risk-adjusted short- and long-term outcomes for on-pump versus off-pump coronary artery bypass surgery. 
  • Rituximab in lymphocyte predominance Hodgkin's disease: a case series. 
  • Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. 
  • Role of Ethnicity and Geographic Location on Glioblastoma IDH1/IDH2 Mutations. 
  • Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. 
  • Routine use of zoledronic acid in early-stage breast cancer. 
  • Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. 
  • SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia. 
  • Safety and Clinical Outcomes of Catheter Ablation of Atrial Fibrillation in Patients With Chronic Kidney Disease. 
  • Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab. 
  • Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study. 
  • Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study. 
  • Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. 
  • Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. 
  • Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. 
  • Second primary malignancies following the treatment of early stage ovarian cancer: update of a study by the National Cancer Institute of Canada--Clinical Trials Group (NCIC-CTG). 
  • Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes. 
  • Selective neck dissection for the treatment of neck metastasis from squamous cell carcinoma of the head and neck. 
  • Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. 
  • Sentinel Lymph Node Biopsy for Recurrent Melanoma: A Multicenter Study. 
  • Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat? 
  • Sentinel lymph node biopsy following a rotational flap. 
  • Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906. 
  • Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. 
  • Serial echocardiographic evaluation of restenosis after successful percutaneous mitral commissurotomy. 
  • Serum protein profiling using an aptamer array predicts clinical outcomes of stage IIA colon cancer: A leave-one-out crossvalidation. 
  • Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. 
  • Should Ki67 immunohistochemistry be performed on all lesions in multifocal small intestinal neuroendocrine tumours? 
  • Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. 
  • Significance of microRNA-related variants in susceptibility to recurrence of oropharyngeal cancer patients after definitive radiotherapy. 
  • Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens. 
  • Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer. 
  • Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD. 
  • Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. 
  • Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. 
  • Sleeve lobectomy for non-small cell lung cancer with N1 nodal disease does not compromise survival. 
  • Small bowel intussusception and laparoscopy. 
  • Solid pseudopapillary neoplasm of the pancreas: clinicopathologic and survival analyses of 64 cases from a single institution. 
  • Sphincter-sparing surgery in patients with low-lying rectal cancer: techniques, oncologic outcomes, and functional results. 
  • Sphincter-sparing treatment for distal rectal adenocarcinoma. 
  • Squamous cell carcinoma arising in inverted papilloma. 
  • Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence. 
  • Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. 
  • Statin use and need for therapy in chronic lymphocytic leukemia. 
  • Stereotactic body radiation therapy for curative treatment of adrenal metastases. 
  • Stereotactic body radiation therapy versus sublobar resection for stage I NSCLC. 
  • Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. 
  • Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer. 
  • Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. 
  • Stress cardiac magnetic resonance imaging provides effective cardiac risk reclassification in patients with known or suspected stable coronary artery disease. 
  • Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. 
  • Sunitinib efficacy against advanced renal cell carcinoma. 
  • Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. 
  • Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. 
  • Supratentorial hemispheric ependymomas: an analysis of 109 adults for survival and prognostic factors. 
  • Surgeon volume and adequacy of thyroidectomy for differentiated thyroid cancer. 
  • Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review. 
  • Surgical management of Merkel cell carcinoma. 
  • Surgical management of cutaneous melanoma: current practice and impact on prognosis. 
  • Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma: what is the optimal timing? 
  • Surgical resection for small hepatocellular carcinoma. 
  • Surgical resection is necessary to maximize tumor control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of the head and neck (stage III and IV). 
  • Surgical staging for endometrial cancer in the elderly - is there a role for lymphadenectomy? 
  • Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. 
  • Survival Advantage With Adjuvant Chemotherapy for Locoregionally Advanced Rectal Cancer: A Veterans Health Administration Analysis. 
  • Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer. 
  • Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy. 
  • Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. 
  • Survival analysis of presumptive prognostic markers among oligodendrogliomas. 
  • Survival and low-grade glioma: the emergence of genetic information. 
  • Survivorship care planning and its influence on long-term patient-reported outcomes among colorectal and lung cancer survivors: the CanCORS disease-free survivor follow-up study. 
  • Synchronous bilateral testicular tumour: nonseminomatous germ cell tumours and contralateral benign tumours. 
  • Systematic biopsies: do they add prognostic information in men with clinically localized prostate cancer treated with radiation therapy alone? 
  • Systematic review and consensus definitions for standardised endpoints in perioperative medicine: postoperative cancer outcomes. 
  • T classification and clivus margin as risk factors for determining locoregional control by radiotherapy of nasopharyngeal carcinoma. 
  • TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. 
  • TGFβ1 Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy. 
  • Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). 
  • Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies. 
  • Targeting slow-proliferating ovarian cancer cells. 
  • Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. 
  • Technical modifications and outcomes after Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) for primary liver malignancies: A systematic review. 
  • Temozolomide in pediatric low-grade glioma. 
  • Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. 
  • Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure). 
  • Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. 
  • Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. 
  • Textbook Outcomes Among Patients Undergoing Retroperitoneal Sarcoma Resection. 
  • Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. 
  • The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surveillance and Survivorship Care of Patients After Curative Treatment of Colon and Rectal Cancer. 
  • The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). 
  • The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial. 
  • The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer. 
  • The Influence of Fat Grafting on Breast Imaging after Postmastectomy Reconstruction: A Matched Cohort Analysis. 
  • The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521. 
  • The MEMORY Study: MulticentEr study of Minimally invasive surgery versus Open Radical hYsterectomy in the management of early-stage cervical cancer: Survival outcomes. 
  • The Oldest Old: A National Analysis of Outcomes for Patients 90 Years or Older With Lung Cancer. 
  • The Optimal Timing of Stage 2 Palliation for Hypoplastic Left Heart Syndrome: An Analysis of the Pediatric Heart Network Single Ventricle Reconstruction Trial Public Data Set. 
  • The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. 
  • The Prognostic Value of CD44 Expression in Epithelial-Mesenchymal Transition: Preliminary Data from Patients with Gastric and Esophageal Cancer. 
  • The Role of Opioids and Their Receptors in Urological Malignancy: A Review. 
  • The S1103Y cardiac sodium channel variant is associated with implantable cardioverter-defibrillator events in blacks with heart failure and reduced ejection fraction. 
  • The Use of Re-irradiation in Locally Recurrent, Non-metastatic Rectal Cancer. 
  • The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. 
  • The challenge of systematic reviews of diagnostic and staging studies in cancer. 
  • The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. 
  • The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma. 
  • The current clinical value of the DCIS Score. 
  • The effect of beta-adrenergic blockers on the prognostic value of peak exercise oxygen uptake in patients with heart failure. 
  • The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost. 
  • The effect of natural killer cell killer Ig-like receptor alloreactivity on the outcome of bone marrow stem cell transplantation for severe combined immunodeficiency (SCID). 
  • The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study. 
  • The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. 
  • The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). 
  • The effects of health changes on projections of health service needs for the elderly population of the United States. 
  • The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. 
  • The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. 
  • The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. 
  • The expression of Claudin-4 in gastric cancer tissue: A single center experience. 
  • The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy. 
  • The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. 
  • The imaging viewpoint: how imaging affects determination of progression-free survival. 
  • The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. 
  • The impact of 5-fluorouracil and intraoperative electron beam radiation therapy on the outcome of patients with locally advanced primary rectal and rectosigmoid cancer. 
  • The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases. 
  • The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer. 
  • The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. 
  • The outcome of resected cystic pancreatic endocrine neoplasms: a case-matched analysis. 
  • The pediatric preclinical testing program: description of models and early testing results. 
  • The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. 
  • The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa. 
  • The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer. 
  • The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. 
  • The role of adenotonsillectomy in graft-versus-host disease. 
  • The role of androgen deprivation therapy combined with prostate brachytherapy. 
  • The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma. 
  • The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL. 
  • The role of targeted therapy in the treatment of colorectal cancer. 
  • The roles of MASPIN expression and subcellular localization in non-small cell lung cancer. 
  • The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer. 
  • The value of follow-up FDG-PET/CT in the management and prognosis of patients with HPV-positive oropharyngeal squamous cell carcinoma. 
  • The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. 
  • Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). 
  • Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. 
  • Third prize: the role of endoscopic nephron-sparing surgery in the management of upper tract urothelial carcinoma. 
  • Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. 
  • Time-dependent risk reduction of ventricular tachyarrhythmias in cardiac resynchronization therapy patients: a MADIT-RIT sub-study. 
  • Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate. 
  • Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. 
  • Timing of cardiac transplantation in patients with heart failure receiving beta-adrenergic blockers. 
  • Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke. 
  • Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy. 
  • Transfusion of blood components containing ABO-incompatible plasma does not lead to higher mortality in civilian trauma patients. 
  • Transplant-Free Survival and Interventions at 6 Years in the SVR Trial. 
  • Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research. 
  • Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. 
  • Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. 
  • Trastuzumab emtansine for HER2-positive advanced breast cancer. 
  • Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. 
  • Traveling to a High-volume Center is Associated With Improved Survival for Patients With Esophageal Cancer. 
  • Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? 
  • Treating the biochemical recurrence of prostate cancer after definitive primary therapy. 
  • Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry. 
  • Treatment of adults with acute lymphoblastic leukemia: do the specifics of the regimen matter?: Results from a prospective randomized trial. 
  • Treatment of patients with pineoblastoma with high dose cyclophosphamide. 
  • Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. 
  • Trends and outcomes in the use of surgery and radiation for the treatment of locally advanced esophageal cancer: a propensity score adjusted analysis of the surveillance, epidemiology, and end results registry from 1998 to 2008. 
  • Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. 
  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. 
  • Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. 
  • Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. 
  • Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. 
  • Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. 
  • Tumor proliferation in rectal cancer following preoperative irradiation. 
  • U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis. 
  • Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT). 
  • Uncertainty management intervention for older African American and caucasian long-term breast cancer survivors. 
  • Unemployment among adult survivors of childhood cancer: a report from the childhood cancer survivor study. 
  • Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. 
  • Unrelated donor marrow transplantation in children. 
  • Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization. 
  • Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. 
  • Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. 
  • Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. 
  • Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. 
  • Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma. 
  • Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. 
  • Use of intraoperative ablation as an adjunct to surgical resection in the treatment of recurrent colorectal liver metastases. 
  • Usefulness of the QRS score as a strong prognostic marker in patients discharged after undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. 
  • Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. 
  • Utility of functional imaging in prediction or assessment of treatment response and prognosis following thermotherapy. 
  • Uveal melanoma treated with iodine-125 episcleral plaque: an analysis of dose on disease control and visual outcomes. 
  • Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. 
  • Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. 
  • Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. 
  • Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer. 
  • Variants in nucleotide excision repair core genes and susceptibility to recurrence of squamous cell carcinoma of the oropharynx. 
  • Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. 
  • Venous Invasion in Pancreatic Neuroendocrine Tumors Is Independently Associated With Disease-free Survival and Overall Survival. 
  • Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. 
  • Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. 
  • Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma: Considering Alternative Treatment Approaches. 
  • Vitamin D Supplementation and Prevention of Type 2 Diabetes. 
  • Volume of resection in patients treated with breast conservation for ductal carcinoma in situ. 
  • Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. 
  • Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. 
  • Warfarin use and long-term outcomes in patients with acute myocardial infarction and atrial fibrillation. 
  • Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. 
  • Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. 
  • Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. 
  • Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. 
  • Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. 
  • Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact? 
  • What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer. 
  • What's new in neoadjuvant therapy for breast cancer? 
  • Whole-exome sequencing identifies novel somatic alterations associated with outcomes in idiopathic multicentric Castleman disease. 
  • Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. 
  • Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. 
  • [Surgical treatment of malignant esophageal tumors in PUMC Hospital]. 
  • miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. 
  • miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. 
  • p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers. 
  • p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. 
• 

  Keywords of People

  • Abbruzzese, James, D. C. I. Distinguished Professor of Medical Oncology, Medicine, Medical Oncology
  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Charles, Hal Cecil, Adjunct Associate Professor in the Department of Radiology, Radiology
  • Esclamado, Ramon Mitra, Richard Hall Chaney, Sr. Distinguished Professor Emeritus of Otolaryngology, Head and Neck Surgery & Communication Sciences
  • Halabi, Susan, Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Hanks, Brent A., Associate Professor of Medicine, Pharmacology & Cancer Biology
  • Lee, Walter T, Professor of Head and Neck Surgery & Communication Sciences, Radiation Oncology
  • Milano, Carmelo Alessio, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • Mruthyunjaya, Prithvi, Adjunct Associate Professor in the Department of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Palmer, Gregory M., Associate Professor of Radiation Oncology, Radiation Oncology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology
  • Reed, Shelby Derene, Professor in Population Health Sciences, Duke Science & Society
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Sullivan, Daniel Carl, Professor Emeritus of Radiology, Radiology
  • Yancy Jr., William Samuel, Professor of Medicine, Medicine, General Internal Medicine
  • Zafar, Syed Yousuf, Adjunct Professor in the Department of Medicine, Duke Science & Society